Verrucous Psoriasis: Rare Variant and Novel Treatment
180401804018040
JDD authors Dimitra Xenopoulou MS, Christopher Pochat MS, and Evelyn Greco DO present the findings of a successful treatment for verrucous psoriasis.
CASE
A 64-year-old female presented to the outpatient clinic for the evaluation of flaking and itchy lesions on her bilateral hands and feet that were present for several months and caused difficulty with activities of daily living. Inconsist …
JDD authors Dimitra Xenopoulou MS, Christopher Pochat MS, and Evelyn Greco DO present the findings of a successful treatment for verrucous psoriasis.
CASE
A 64-year-old female presented to the outpatient clinic for the evaluation of flaking and itchy lesions on her bilateral hands and feet that were present for several months and caused difficulty with activities of daily living. Inconsist … Continue reading "Verrucous Psoriasis: Rare Variant and Novel Treatment"
A 92-year-old female patient presents with complaints regarding her nails. She states they often crumble, and have been yellowish in color for years. Her toenails are so thickened that it is difficult to trim them. She is otherwise asymptomatic and has no fingernail involvement. What is the most common cause of this patient's condition?
A. Tinea manuum
B. Tinea pedis
C. Inflammatory d … 
Dermatophyte infections are estimated to affect about 25% of the world’s population, representing some of the most common infections in the world. Conditions such as onychomycosis and tinea capitis may significantly impact quality of life by way of their symptoms or appearance, making adequate treatment important. Oral and topical formulations of terbinafine are commonly used on- and off-label f … 
Have you received your August issue of the JDD yet? This month's issue contains a special focus on Psoriasis, as August is Psoriasis Awareness Month! Below are the issue highlights and Editor Picks for the August issue of JDD!
In Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years, high levels of effi … 